Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Trial Profile

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs AZD 6738 (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Vistusertib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HUDSON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Oct 2018 Planned End Date changed from 2 Nov 2020 to 30 Jul 2021.
    • 19 Oct 2018 Planned primary completion date changed from 2 Nov 2020 to 30 Jul 2021.
    • 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top